ARCHIVE 2009
WindSim
(December 2009)
WindSim participated in the Bolund blind tests for Wind Simulation Tools.
WindSim particpated in the Bolund experiment, a new validation case undertaken by Risø. The CFD methods—including WindSim—showed the lowest errors among the various methods used. The Bolund experiment is a field campaign that provides a new dataset for validating numerical models of flow in complex terrain and is the basis for a unique blind comparison of flow models. Today, many flow models are evaluated against hill experiments of simple geometry often performed at laboratory scales in wind tunnels. However, in order to validate the models, full scale field experiments with realistic terrain forms are necessary. The Bolund experiment allows such a validation.
More information can be found here
Vaccibody
(21.12.09)
Vaccibody gets thorough coverage in”Genialt nr 4 – 2009”
Vaccibody – a novel, new vaccine invention
The Norwegian company Vaccibody AS focuses on developing more efficient vaccines against bacteria, viruses and cancer. Through our new approach, we have managed to develop a vaccine which specifically targets key cells of the immune system.
”Genialt” is published by the Norwegian Biotechnology Advisory Board
Vaccibody
(13.12.09)
Vaccibody in project looking at the development of possibly the world’s first vaccine against food allergy.
The project is a collaboration between researchers from the veterinary institute, the University of Oslo, the Norwegian National Hospital (Rikshospitalet), Haukeland Univeristy Hospital, Vaccibody AS which possesses the IPR pertaining to the linkage molecule, and the Italian Public Health Institute. Researchers from the university of Oslo, the Norwegian National Hospital (Rikshospitalet), and Haukeland Univeristy Hospital will be responsible for recruitment of patients with shellfish allergy. The project is supported by the Norwegian Research Council through the EUREKA program.
Sorbwater
(12.12.09)
Sorbwater featured in Finansavisen
Water cleaning is a billion dollar market which is experiencing strong growth . Norwegian entrepreneurs wish to compete amongst the best in the world.
Weyland
(06.12.09)
Weyland gets extensive coverage in Bergen’s main local daily newspaper, Bergensavisen.
Weyland
(04.12.09)
Weyland gets broad coverage in one of Norway’s main financial newspapers, Finansavisen.
Sorbwater
(02.12.09)
Sorbwater honoured with ”Best Company Presentation Award” and voted “Most Promising Company” at the CONNECT Nordic Cleantech Partnerforum 2. desember 2009 i Bergen.
CONNECT Nordic Cleantech Partnerforum took place on December 2 with the participation of over 125 delegates from the Nordic countries. The forum assembled participants from different fields including leading power generation companies, venture capital firms and Cleantech technology providers. A total of 15 companies presented innovative and environmentally friendly commercialization concepts.
Torgeir Nærø receiving the ”Best Company Presentation Award” on behalf of Sorbwater AS from Solveig Holm, the managing director of CONNECT Vest.
Vaccibody
(01.12.09)
Vaccibody gets broad coverage in Genetic Engineering.
The article entitled “Big Pharma's Interest in Vaccine Products on Rise” highlights Vaccibody as one of the main innovative companies within the field of vaccine therapy to present at The World Vaccine Congress in Lyon last October.
Read more
Weyland
(17.11.09)
Weyland to carry out a feasibility study for the construction of a second generation bioethanol production facility at Hurum, Norway.
Read article from INDUSTRIEN here
Read article from Røyken and Hurum newspaper here
Read article from www.skog.no here
Hepmarin AS receives grant
(03.11.09)
Sarsia Seed portfolio company Hepmarin AS has received € 41.000 as a grant from Innovation Norway
Windsim launches new web
(29.10.09)
Windsim launches new website www.windsim.com in response to continued company growth.
New Chief Executive Officer at Sorbwater Technology AS
(29.10.09)
Sorbwater Technology AS has appointed Torgeir Nærø as its new chief executive officer. Torgeir brings extensive management experience from various companies including Nera, Nokia and Gexcon. The company has also recently launched its new website www.sorbwater.com.
Vaccibody presents results from new influenza studies
(29.10.09)
The presentation was given by the company’s CEO, Ole Henrik Brekke, at the World Vaccine Congress held in Lyon 5-8 October, and covered the company’s ongoing influenza program currently being carried out in collaboration with the National Hospital of Norway.
Read more
Weyland gets local broadsheet coverage in Bergens Tidende, Friday October 9, 2009
(28.10.09)
The company is financed through investments from Fana Stein og Gjenvinning, Sparebanken Vest (new investor) and Sarsia Seed, in addition til grants from Statoil Hydro and Innovation Norway. A total of 7 mUSD has been invested to date in the pilot plant which is located at Flesland on the outskirts of Bergen. The scheduled completion date for the plant has been set for the end of this year.
Comprehensive Coverage of Vaccibody in Weekend Edition (12/13 September 2009) of Dagens Næringsliv*
(16.09.09)
As one of Norway’s few biotech companies with products able to potentially revolutionise current drug-based therapies, Vaccibody develops cost-efficient “next generation” vaccines which can be produced rapidly against a wide spectrum of diseases. This, coupled with the fact that the company’s products have the potential to achieve blockbuster (billion dollar) level status, formed the basis for the news paper’s three-page coverage of Vaccibody. For further information regarding the article please contact Sarah Hambro at Dagens Næringsliv (sarah.hambro@dn.no).
(*Dagens Næringsliv is one of Norway’s most popular business newpapers and the world's best-read daily business newspaper per capita covering Norwegian and International business and specialised coverage of non-business related topics).
New Chief Executive Officer and Strengthened Board of Directors at Weyland AS
(01.09.09)
Weyland AS has appointed Petter Bartz-Johannessen as chief executive officer with effect from 01 September 2009. Petter was most recently marketing director at Aibel AS. The company’s board, which is currently chaired by Jacob Bleie, a former executive vice president at Statoil, has also been strengthened with the appointment of Karstein Lien, vice president at Sparebanken Vest, in connection with Sparebanken Vest’s new placement in Weyland AS.
Vaccibody AS making headlines
(18.06.2009)
The World Health Organisation recently (11 June 2009) officially declared the current outbreak of swineflue (aka influenza A and H1N1) to be a global pandemic disease. The need to treat the disease and to prevent its occurrence can only be met by vaccines which may be used prior to, during and following such a serious outbreak. Vaccibody is uniquely positioned to take on not only this but also other disease challenges.
Sarsia Seed invests in Vaccibody AS
(10.06.09)
Sarsia Seed has invested NOK 2 mill (€ 250.000) in the company Vaccibody. The company, which is a is spin-out from The University of Oslo and The Rikshospitalet University Hospital, has developed a new concept in vaccine treatment which has the potential to not only improve the efficacy of traditional prophylactic vaccines but also allows for the therapeutic use of vaccines in the active treatment of problematic infectious diseases like herpes, HIV and influenza. The technology also has the potential to give rise to therapeutic vaccines against certain types of cancer.
WindSim and AXYS Join Forces to Help Offshore Wind Developers
(19.05.09)
BOSTON, MA--(May 18, 2009) - WindSim today announced that it has initiated a strategic partnership with AXYS Technologies Inc. (AXYS) aimed at helping wind developers design more profitable offshore wind farms.
WindSim's wind farm design software will be bundled with every sale of the recently launched AXYS WindSentinel™ offshore wind resource assessment buoy. The complementary advanced technologies provide a compelling combination of new offshore wind data collection techniques with proven wind farm design and modeling tools.
Weyland AS is recruting CEO.
(04.05.09)
Weyland is strengthening it`s organization and is recruiting a CEO. The new CEO will get the overall responsibility for development of the company and its technology towards a positions as an important player in the biofuel market.
Read more
Volusense AS receives grant
(22.04.09)
Volusence has received € 740.000 as a grant from Innovation Norway to a project for clinical documentation of the company´s respirometry products and for development of miniaturised version of the company´s instrument for assessment of lung function.
WindSim AS Launches US Subsidiary
(15.04.09)
BOSTON, MA--(Marketwire - April 15, 2009) - Norway's WindSim AS today announced the launch of WindSim AMERICAS Inc. to meet the increased demand for its advanced software solutions and professional services that help worldwide wind energy industry leaders design more profitable wind farms. Software Industry Veteran Robert D. Buckley is Appointed as President.
Read more
New version of WindSim released.
(15.04.09)
WindSim has released version 4.9 of the Wind Farm Design Tool WindSim”. WindSim is a simulator for optimizing the energy production from wind turbines and planning of wind farms. WindSim is based on Computational Fluid Dynamics, CFD and is used by industry leaders.
The new features include:
- Temperature coupling
- Coupling with meteorological models
- Handling 10 million cell models
- Conversion of high resolution terrain data including vegetation height
- New turbulence closures
- Checking the IEC standard; shear, turbulence, extreme wind
- Energy optimization
- Time history input and output; prognosis of the Annual Energy Production
- Excel compatible output
Read more
Screen Cancer enters distribution agreement
ScreenCancer AS has entered an agreement with U.S. based Quest Diagnostics Incorporated (NYSE: DGX), Quest for the distribution of its colorectal cancer screening test insure ® FIT ™ In 24 countries in Europe.
Read more
Volusense expands staff
(01.01.09)
Elin Øglend Bredeli has joined Volusense AS as a clinical application specialist. Her main responsibility will be support to users of Volusense respirometry equipment.
» Read more
Article on Hepmarin AS in UMB Nytt
UMB-nytt the campus newspaper on The Norwegian University of Life Sciences prints a large story on the people behind Hepmarin and the company´s process for purification of heparin from marine raw materials.
» Read more
Article on Biofuel and Weyland AS in Finansavisen
(17.01.09)
Norwegain business newspaper Finansavisen prints an article on Weuland AS and the company´s process for production of cellulostic ethanol.
» Read more
Sarsia partner presents at Conference on Metabolic Diseases
(03.09.09)
Dr Abdi-Dezfuli gives an overview of challenges associated with the funding of prospects aiming to develop therapies against the metabolic syndrome at SMi’s 2nd Conference on Metabolic Diseases, London, 24-25 September 2008.
» Download Presentation
WindSim AS achieves record growth in 2008
With growth comes change, so we are delighted to announce that we have outgrown our former location and now reside in new offices.
» Read more
Volusense AS starts clinical verification studies
Volusense AS has started clinical verification studies in four European hospitals. Studies on different medical indications targeted by Volusense`s respirometry technology have been initiated at Haukeland Universitety Horpital Bergen, Royal Alexandra Children´s Hospital Brighton, University Children´s Hospital Bern and Department of Child Health University of Cardiff.
Volusense AS gets patent granted
Sarsia Seed portfolio company Volusense AS has been informed that they will get a patent covering the company´s core technology granted in Australia and China. The patent has already been granted in Japan and USA.
» Read more